Gilead Sciences made $3 billion selling the drug, used to prevent the spread of HIV, last year.

Like any new treatment, there may be misconceptions surrounding PrEP - but if we shy away from discussing it, we are doing a disservice to the thousands of New Yorkers who could benefit from it - particularly those who have a disproportionately higher risk of HIV infection

AIDS guilt for men of my generation isn't a thing so much as it is an implant. We're punished for that too, not by our peers but by our millennial friends, understandably not wishing to be defined by death.